Drug reference
darbepoetin
Erythropoiesis-stimulating agent · Haematinic
Erythropoiesis-stimulating agentHaematinicATC B03XA02
CDSCO approvedATC B03XA02
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
C
FDA category + note
Mechanism
A hyperglycosylated modified erythropoietin that stimulates erythropoiesis.
Indications
Anaemia of chronic renal failureAnaemia in AIDS patients treated with zidovudineCancer chemotherapy induced anaemiaPreoperative increased blood production for autologous transfusion during surgery
Dosing
- Adult
- Administered once every 2–4 weeks.
Pharmacokinetics
Half-life
>24 hours (plasma)
Pregnancy & lactation
Pregnancy
C
Related guidelines
Blood transfusion in obstetrics and gynaecology
FOGSI · Obstetrics & Gynaecology · 2024
Preoperative cardiac evaluation for non-cardiac surgery
AHA · Cardiology · 2025
Breast cancer
ICMR · Oncology · 2022
Iron deficiency anaemia in pregnancy
FOGSI · Obstetrics & Gynaecology · 2017
Breast cancer
ESMO · Oncology · 2024
Other Erythropoiesis-stimulating agent drugs
Ask House about darbepoetin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team